KCT0008074尚未招募未知
A dose-block randomized, double-blind, placebo-controlled, single and multiple ascending dose, first-in-human, phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics after subcutaneous administration of C1K in healthy subjects
Ensol Biosciences0 个研究点目标入组 35 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 45(Year)（—）
- 性别
- All
入选标准
- •1) Healthy subjects aged 19 - 45 years at the time of screening visit procedure.
- •2) The subject weighs in the range of 50.0 - 90.0 kg and has a body mass index (BMI) in the range 18-27 kg/m2.
- •3) Sufficient ability to understand the study after being informed about the study and provide written informed consent.
- •4) Based on physical examination, vital sign, 12-lead ECG and laboratory test etc. and in the opinion of the investigator, the subject is suitable for the study.
排除标准
- •1) A subject with clinically significant hepatobiliary, renal, neurologic, respiratory, endocrine, blood•oncology, cardiovascular, urinary, or, psychical diseases or a history
- •2) A subject who has difficulty with sub-cutaneous injection(ex: tattoo, allergy on skin etc.)
- •3)A subject who has hypersensitivity to the drugs of the drugs containing the same class, or other drugs, or a history of clinically significant hypersensitivity
- •4) A subject who has ventricular tachycardia, ventricular tachycardia, ventricular flutter or confirmed other ventricular flutter and QTc interval: > 450 ms or the other clinically significant medical findings
- •5)A subject with the following results in the screening test:
- •- Blood AST (GOT), ALT (GPT): > Normal range upper × 1.5
- •- Blood CPK > Normal range upper × 1.5
- •- eGFR (CKD-EPI equation) < 60 mL/min/1.73 m2
- •6) Positive serological test (syphilis test, hepatitis B test, hepatitis C test, human immunodeficiency virus (HIV) test)
- •7) A subject with the following results in the screening test:
- •- systolic blood pressure < 80 mmHg or > 140 mmHg
- •- diastolic blood pressure < 50 mmHg or > 90 mmHg
- •8)A subject with a history of drug abuse or positive urine screening test for drug abuse
- •9)A subject who administered any prescription drugs or herbal medicine within 2 weeks prior to the expected date of the first dose, or any over-the-counter drug (OTC drug) or vitamin within 1 week prior to the expected date of the first dose (However, can participate in the study if otherwise decided eligible by the investigator).
- •10) A subject who participated in other clinical trial and administered investigational drug within 6 months prior to the expected date of the first dose
- •11) A subject who donated whole blood within 2 months or the component blood within 1 month prior to the expected date of the first dose, or received blood transfusion within 1 month prior to the expected date of the first dose
- •12)Smokers who smoke more than 10 cigarettes/day in the last 3 months as of screening day.
- •13)A subject with persistent alcohol intake (> 21 units/week, 1 unit = 10 g of pure alcohol), or inability to abstain from drinking from 3 days before the expected date of the first dose until the last discharge
- •14)A male subject who has plan to have a baby or to donate sperm. A female subject who is pregnant or lactating or has plan to lactate within 3 months after administration of IP
- •15) A subject who is intending to become pregnant during this study or with inability to use a medically acceptable contraception method(ex. sterilization operation, intrauterine device etc. for Subject or subject’s partner
- •? medically acceptable contraception method
- •- Use of intrauterine device which is proven pregnancy failure rates in spouses (or partners).
- •- Use combined blocking contraceptives (for male or female) and antiseptic drugs
- •- Subject or partner’s operation(vasectomized, bilateral tubal occlusion, hysterectomy)
- •16) Subject who is considered inadequate to participation in the study due to other reason under investigator’s discretion
研究者
相似试验
招募中
不适用
A dose-block randomized, double-blind, placebo-controlled, single dosing, dose-escalation phase I clinical trial to investigate the safety/tolerability and pharmacokinetics/pharmacodynamics of CKD-519 after oral administration in healthy adult volunteersDiseases of the circulatory systemKCT0001159Chong Kun Dang40
已完成
不适用
A dose-block randomized, double-blind, placebo-controlled, single dosing, dose-escalation phase I clinical trial to investigate the safety/tolerability and pharmacokinetics of HNP-2006 after intravenous administration in healthy adult volunteersKCT0005257Hana Pharm40
招募中
不适用
A dose-block randomized, double-blind, placebo-controlled, single/multiple dosing, dose-escalation phase I clinical trial to investigate the safety/tolerability and pharmacokinetics of DW2008S after oral administration in healthy male subjectsDiseases of th respiratory systemKCT0004125Dongwha Pharmaceutical64
招募中
不适用
A dose block-randomized, double-blind, placebo-controlled, single/multiple dosing, dose-escalation clinical phase 1 trial to investigate the safety, tolerability, and pharmacokinetics of DWP09031 after oral administration in healthy male subjectsKCT0000343Inje University Busan Paik Hospital64
已完成
不适用
Phase 1 study for NASHKCT0005295J2H Biotech100